Intact Investment Management Inc. Buys 53,300 Shares of Medtronic PLC $MDT

Intact Investment Management Inc. raised its stake in Medtronic PLC (NYSE:MDT) by 132.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 93,500 shares of the medical technology company’s stock after buying an additional 53,300 shares during the period. Intact Investment Management Inc.’s holdings in Medtronic were worth $8,905,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of MDT. Delos Wealth Advisors LLC purchased a new stake in shares of Medtronic in the second quarter valued at approximately $27,000. Corundum Trust Company INC purchased a new position in Medtronic during the 3rd quarter valued at about $27,000. Steigerwald Gordon & Koch Inc. bought a new stake in shares of Medtronic in the 3rd quarter valued at about $33,000. Tripletail Wealth Management LLC purchased a new stake in shares of Medtronic in the 3rd quarter worth approximately $34,000. Finally, GFG Capital LLC purchased a new stake in shares of Medtronic in the 2nd quarter worth approximately $36,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

MDT has been the subject of a number of recent research reports. William Blair raised shares of Medtronic from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 6th. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a research note on Friday. Royal Bank Of Canada raised their price objective on Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Finally, Stifel Nicolaus boosted their target price on shares of Medtronic from $90.00 to $105.00 and gave the stock a “hold” rating in a report on Thursday, October 9th. Fourteen investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat, Medtronic currently has an average rating of “Moderate Buy” and an average target price of $110.28.

Medtronic Trading Down 0.4%

Shares of Medtronic stock opened at $100.98 on Monday. The stock has a market cap of $129.45 billion, a PE ratio of 27.22, a price-to-earnings-growth ratio of 2.66 and a beta of 0.71. The firm has a fifty day moving average price of $99.44 and a 200 day moving average price of $95.32. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.31 by $0.05. The company had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm’s revenue was up 6.6% on a year-over-year basis. During the same period in the prior year, the company earned $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts predict that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 2.8%. The ex-dividend date was Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is currently 76.55%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).